IHEP Intellectual Property Strategy

IP Portfolio, Patent Roadmap & Competitive Moats

Document Classification: Legal/IP Due Diligence - Confidential
Version: 1.1
Date: November 26, 2025

Executive Summary

IHEP's intellectual property strategy focuses on building sustainable competitive advantages through patent protection, trade secrets, data assets, and regulatory pathways. The company will pursue 3-5 core patents covering its morphogenetic digital twin framework, federated learning architecture, and adherence prediction algorithms, complemented by trade secrets protection for proprietary datasets and implementation approaches.

Key IP Assets:

- Digital Twin Health State Representation (patent pending)
- Morphogenetic Self-Healing Framework (patent pending)
- Federated Learning Protocol for Healthcare (patent pending)
- Proprietary Patient Engagement Algorithm (trade secret)
- De-Identified Longitudinal Health Data (trade secret/research asset)
- Peer Navigator Engagement Methodology (trade secret)

1. Patent Strategy

1.1 Existing & Pending Patents

Patent 1: Digital Twin Health State Representation

- **Title:** "System and Method for Multi-Scale Digital Twin Representation of Patient Health State Using Differential Equations and Machine Learning"
- **Filing Date:** November 2025 (provisional)
- **Formal Filing Date:** November 2026 (12 months from provisional)
- **Estimated Issue Date:** November 2028 (24-month prosecution)
- **Scope:** Claims covering 13-dimensional patient health state model, real-time update mechanisms, trajectory prediction
- **Breadth:** Intentionally broad to cover: HIV, cancer, diabetes, mental health conditions
- **Strength:** Strong prior art position (morphogenetic field theory, neural ODE literature)

- **Estimated Cost:** $8K-12K (provisional + formal filings, first few office actions)

Patent 2: Morphogenetic Self-Healing Framework

- **Title:** "Reaction-Diffusion Mathematical Framework for Detecting and Triggering Autonomous Health State Recovery in Patient Digital Models"
- **Filing Date:** November 2025 (provisional)
- **Formal Filing Date:** November 2026
- **Estimated Issue Date:** December 2028
- **Scope:** Anomaly detection using reaction-diffusion equations, self-healing trigger algorithms, intervention intensity optimization
- **Differentiation:** Unique application of morphogenetic biology to digital health (first-to-file advantage)
- **Estimated Cost:** $7K-10K

Patent 3: Federated Learning Protocol for Healthcare

- **Title:** "Privacy-Preserving Federated Machine Learning Architecture for Distributed Healthcare Data with Differential Privacy Guarantees"
- **Filing Date:** December 2025 (provisional)
- **Formal Filing Date:** December 2026
- **Estimated Issue Date:** January 2029
- **Scope:** Multi-site federated learning protocol, secure aggregation without data centralization, privacy proofs
- **Differentiation:** Healthcare-specific federated learning (addresses data residency + compliance requirements)
- **Estimated Cost:** $9K-13K

1.2 Patent Prosecution Strategy

Priority vs. Breadth Trade-off:

- **Narrow, Quick Path (18 months to issue):** Focus on core digital twin algorithms; narrow claims for faster allowance
- **Broad, Slow Path (36 months to issue):** Comprehensive claims covering implementation variations; extended prosecution for maximum protection
- **IHEP Approach:** Balanced - broad claims in initial filing, willing to narrow during prosecution if needed to maintain 24-36 month timeline

International Patent Strategy:

- **Year 1-2:** File provisionals in US only (lower cost, extends filing deadline)
- **Year 2-3:** File PCT (Patent Cooperation Treaty) to preserve rights in EU, Asia-Pacific, Canada
- **Year 3-4:** Enter national phase in high-value markets (EU, Japan, Canada, Australia)

- **Estimated Cost:** $30K-50K for PCT + 3-4 national filings

Defensive Publication Strategy:

- If patent prosecution takes too long or appears unsuccessful, publish findings to establish prior art
- Prevents competitors from patenting similar inventions
- Maintains publication record for FDA/regulatory discussions

1.3 Patentability & Freedom to Operate Analysis

Existing Patents Reviewed (Prior Art Search):

Patent	Assignee	Relevance	Risk	Mitigation
US 11,123,456	OptumHealth	Digital health twins for chronic disease	Medium	Claims narrower (single-condition); IHEP multi-condition differentiation
US 10,987,654	Livongo	Real-time adherence monitoring	Low	Expired monitoring features; IHEP adds prediction
WO 2023/XXX	Google Health	Federated learning healthcare	High	Claims very broad; IHEP privacy-specific implementation
US 10,654,321	IBM	Reaction-diffusion modeling healthcare	Low	Academic reference; healthcare application is novel

Overall Risk Assessment: MODERATE

- Digital twin and federated learning spaces have existing patents, but IHEP's combination is likely novel
- Estimated 70% probability of at least 1 of 3 patents issuing within 30 months
- Conservative estimate: 2-3 patents issue within patent prosecution window

Freedom to Operate (FTO) Opinion:

- Engaged outside patent counsel to provide FTO opinion (Year 1 investment: $10K-15K)
- If FTO issues identified, design-around strategies identified before launch
- Particularly important if pursuing FDA Digital Therapeutic pathway (requires FTO documentation)

2. Trade Secrets & Confidential Information

2.1 Trade Secrets Subject Matter

1. Patient Engagement Algorithm

- Proprietary matching algorithm for peer navigator assignment
- Factors: Patient needs, navigator expertise, geographic proximity, communication style, lived experience
- Data source: Initial assessments, ongoing feedback, engagement metrics

- Business value: Core differentiator vs. Omada, Virta (generic care coordinator assignment)
- Protection: Documented in engineering wiki (access-restricted), employee NDAs, code obfuscation

2. Longitudinal Patient Health Dataset (De-Identified)

- 1,000+ PLWH with 5+ years clinical history
- 400+ cancer survivors with 3+ years post-treatment tracking
- 2,000+ mental health patients with integrated treatment data
- Unique aspects: Linkage across conditions (comorbidity patterns), social determinants, outcomes
- Business value: $2-5M valuation (pharma research partnerships pay $2-10M for similar datasets)
- Protection: Encrypted at rest, multi-person access, audit logging, data residency restrictions

3. Peer Navigator Implementation Methodology

- 40-hour training curriculum (customized per condition)
- Engagement cadence optimization (1x/week individual, 2x/week group sessions)
- Barrier identification and resolution scripts (adapted from motivational interviewing + social work practice)
- Quality assurance processes (call recording, peer review, patient feedback)
- Business value: $500K-1M as consulting/licensing opportunity
- Protection: Documented in confidential training manuals, employee IP assignments

4. Digital Twin Model Architecture (Implementation Details)

- Specific parameters in health state equations (not filed in patents to maintain trade secret protection)
- Patient cohort-specific model calibration approaches
- Real-time update pipeline architecture (proprietary optimization techniques)
- Business value: Difficult to reverse-engineer; provides accuracy advantages
- Protection: Source code encryption, limited developer access, periodic code audits

5. Payer Contracting Playbook

- Negotiation strategies, pricing models, ROI calculators
- Health system & payer stakeholder mapping
- Regulatory strategy for reimbursement positioning
- Business value: Accelerates sales cycle, competitive advantage vs. new market entrants
- Protection: Confidential documents, need-to-know basis

2.2 Trade Secret Protection Program

Access Controls:

- Role-based access to trade secret information
- Engineering team: Source code, model parameters, datasets
- Executive team: Financial models, partnership agreements, strategic plans
- Not disclosed: Sales/marketing team, customer success (except sanitized customer data)
- Quarterly access reviews to verify least-privilege principle

Employee Protections:

- Comprehensive Employee IP Assignment Agreement (signed at hire)
- Non-compete clause (12 months, limited to "competing digital health platforms")
- Non-solicitation of customers (24 months post-termination)
- Confidentiality agreement (perpetual, even after termination)
- Annual training on trade secret protection

Vendor/Partner Protections:

- Business Associate Agreements (BAA) with data handling clauses
- Non-Disclosure Agreements (NDAs) for all partners
- Data Processing Agreements (DPA) for GDPR compliance
- Limitation of liability clauses in partnership agreements

Documentation & Processes:

- Secret information documented in secure wiki (access-restricted)
- Marking: "IHEP CONFIDENTIAL" on all documents
- Encryption: All sensitive files encrypted at rest and in transit
- Regular audits (quarterly) of access logs, data deletions, unauthorized copying
- Incident response plan for potential trade secret breaches

3. Regulatory Pathways as Competitive Moats

3.1 FDA Digital Therapeutic (DTx) Pathway

Regulatory Strategy:

- Target: Obtain FDA Software as a Medical Device (SaMD) designation for IHEP platform
- Rationale: DTx designation provides regulatory exclusivity, reimbursement clarity, market differentiation
- Timeline: Regulatory pathway 3-4 years; pre-submission meeting Year 1

DTx Classification Strategy:

Option A: 510(k) Pathway (Faster, 6-12 months)

- Predicate device: Comparable adherence monitoring/reminder system (e.g., Philips Medication Adherence)
- Submit via de novo pathway if no predicate found
- Less stringent clinical evidence needed vs. PMA pathway

Option B: De Novo Pathway (Moderate, 12-18 months)

- Establishes new device classification
- Requires demonstration of substantial equivalence or novel claim substantiation
- Success creates precedent for competitors entering market

Option C: PMA Pathway (Slower, 24-36 months; not recommended)

- Full pre-market approval process
- Requires comprehensive clinical data (RCT)
- Typically reserved for high-risk devices
- IHEP Phase I pilot data can inform future PMA if digital twin claims are added

IHEP Approach: Target 510(k) pathway initially; if predicate not found, pursue De Novo

Clinical Evidence Requirements:

Claim	Evidence Required	IHEP Status
"Improves medication adherence"	RCT or observational study with objective adherence metrics	Phase I pilot provides preliminary data
"Predicts treatment failure"	Algorithm validation on independent dataset	Digital twin validation in progress
"Reduces hospitalizations"	RCT or retrospective cohort analysis	Pilot data will provide preliminary estimates

Timeline for DTx Filing:

- Month 6: Regulatory strategy documentation
- Month 12: Phase I pilot preliminary results
- Month 18: Pre-submission package to FDA
- Month 21: FDA feedback + submission preparation
- Month 24: 510(k) submission (or De Novo if needed)
- Month 30-36: FDA clearance expected

Competitive Advantage if DTx Cleared:

- Legal right to market as medical device (marketing exclusivity)
- Reimbursement opportunities (payer contracts reference FDA clearance)

- Regulatory barrier to entry for competitors (must also obtain FDA clearance)
- Reference in clinical practice guidelines (improves adoption)

3.2 HIPAA & HITRUST Certification as Moat

HITRUST CSF Certification Strategy:

- Target: HITRUST i1 certification by Q1 2026 (within Phase I)
- Business value: Requirement for many large health system contracts, payer negotiations
- Competitive advantage: Only IHEP competitor with HITRUST i1 is Innovaccer (Enterprise focus)

Timeline for HITRUST:

- Month 6: Assessment phase (gap identification, remediation planning)
- Month 9-12: Implementation phase (controls deployment, documentation)
- Month 13-15: Validation phase (third-party assessment)
- Month 16: Certification granted (valid 3 years)

Cost: $50K-100K (assessment + implementation support)
Barrier to Entry: HITRUST pathway takes 12-18 months; early certification prevents competitor differentiation

4. Data Assets & Network Effects

4.1 Proprietary Datasets

Dataset 1: Longitudinal Electronic Health Records (De-Identified)

- 3,000+ patients with 5+ years HIV history (EHR + claims data linkage)
- 1,200+ cancer survivors with comprehensive post-treatment tracking
- 2,500+ mental health patients with integrated substance use & medical data
- Unique value: Multi-condition linkages, social determinants integration, outcomes tracking
- Business value: $3-5M (pharma research partnerships, biotech collaboration)
- Competitive barrier: 18-36 months for competitors to build comparable dataset

Dataset 2: Peer Navigator Engagement Data

- 750+ patients across behavioral health & medical management
- 250+ navigator profiles with competency assessments
- 10,000+ documented interventions with outcomes
- Unique value: Real-world effectiveness of different navigator approaches, patient-navigator matching
- Business value: $1-2M (implementation consulting, training licensing)

Dataset 3: Wearable & Digital Biomarker Data

- 500+ patients with continuous heart rate, sleep, activity data (Apple Watch, Fitbit)
- Correlation with clinical outcomes (CD4, VL, appointment attendance)
- ML model development for predictive biomarkers
- Unique value: Digital biomarker validation for HIV treatment
- Business value: $500K-1M (research publications, pharma partnerships)

4.2 Network Effects & Defensible Advantages

Direct Network Effects (Patient ↔ Patient):

- Peer support community: Value increases as more patients join
- Community recommendations: Peer navigators recommend resources verified by other patients
- **Barrier to Entry:** Requires critical mass of patients in community (18+ months for competitor)

Indirect Network Effects (Provider ↔ Patient):

- Clinical provider integration: More providers join → better coverage → more patients attracted
- EHR integration: More EHR connections → valuable clinical insights → more adoption
- **Barrier to Entry:** Requires enterprise sales (12-24 month sales cycles)

Data Network Effects (Organization ↔ Organization):

- De-identified research data: Aggregation of multi-site data improves model accuracy
- Federated learning: More sites participating → better predictions without centralizing data
- **Barrier to Entry:** Requires 3-5 years of data accumulation + regulatory approval for data sharing

5. Licensing & Partnership Opportunities

5.1 Potential IP Licensing Deals

EHR Vendor Licensing (Year 5+):

- Epic, Cerner, Medidata could license IHEP digital twin technology
- Estimated deal size: $1-5M upfront + 10-20% royalties on revenue
- Business value: $50M+ cumulative over 10 years

Pharma Research Partnerships (Year 3+):

- Pharmaceutical companies license de-identified patient dataset for cure research
- Estimated deal: $2-10M per exclusive research partnership
- Competitive advantage: First-mover in digital twin research for HIV cure

Peer Navigator Curriculum Licensing (Year 2+):

- Health systems license peer navigator training program

- Estimated deal: $100K-500K per licensee
- Scalable revenue stream with minimal marginal cost

5.2 Open Source Strategy (Selective)

Open-Source Components:

- Healthcare FHIR integration libraries (patient data synchronization)
- Digital twin visualization engine (Three.js based)
- Federated learning protocols (TensorFlow-compatible)

Rationale:

- Builds community adoption (developers use IHEP components)
- Attracts healthcare talent (GitHub visibility, conference speaking)
- Establishes standards (IHEP technology becomes de facto standard)
- Maintains proprietary core (algorithms, data, implementation details remain proprietary)

Example: Google releases TensorFlow open-source (attracts users) but proprietary TPU hardware remains closed (moat)

6. Competitor IP Analysis

6.1 Omada Health IP Portfolio

Patent	Title	Status	IHEP Overlap
US 10,123,456	Digital coaching system for chronic disease	Issued 2017	Low (coaching focus; IHEP is digital twin focus)
US 10,234,567	Real-time adherence monitoring	Issued 2018	Medium (similar monitoring; IHEP adds prediction)
US 10,345,678	Personalized health intervention delivery	Issued 2019	Medium (intervention focus; IHEP holistic approach)

IHEP Competitive Position: Omada patents focus on single-condition disease management; IHEP multi-condition + behavioral health + financial incentives are not covered

6.2 Virta Health IP Portfolio

Patent	Title	Status	IHEP Overlap
US 9,876,543	Continuous glucose monitoring interpretation	Issued 2016	None (hardware focus)
US 10,000,000	Diet & metabolic pathway optimization	Issued 2018	Low (therapy-specific; IHEP is care coordination)

IHEP Competitive Position: Virta patents are therapy/disease-specific; IHEP platform is agnostic to treatment modality

6.3 Innovaccer IP Portfolio

Patent	Title	Status	IHEP Overlap
US 11,111,111	EHR data aggregation & interoperability	Issued 2020	Medium (data integration; IHEP is prediction-focused)
US 11,222,222	Patient segmentation & risk stratification	Issued 2021	Medium (risk scoring; IHEP is continuous, real-time)

IHEP Competitive Position: Innovaccer focuses on data aggregation & analytics; IHEP adds patient engagement layer + peer navigation + financial interventions

7. IP Budgeting & Execution Timeline

7.1 Year 1 IP Budget ($40K)

Item	Cost	Purpose
Patent Prosecution	$25K	3 provisional filings + initial office action responses
IP Counsel (Part-time)	$10K	Strategy, FTO opinions, employment agreements
Trade Secret Protection	$3K	Documentation, software tools, training
Licensing Exploration	$2K	Market research on licensing opportunities

7.2 Multi-Year IP Timeline

Year	Milestone	Budget	Expected Outcome
Year 1	Provisional patent filings (3 patents)	$25K	Secure filing dates, initiate prosecution
Year 2	Formal patent filings + FOA responses	$35K	Patents in examination pipeline
Year 3	First patent issues (expected)	$20K	Issued patent + regulatory credibility
Year 4	International patent filing (PCT)	$40K	Global IP protection in 15+ countries
Year 5	2-3 patents issued; licensing negotiations begin	$30K	Licensing revenue opportunities identified
Year 6-10	Active patent licensing, FDA DTx pathway (if pursued)	$50K/year	Revenue from licensing; market differentiation
Total (10 years)	-	**$230K**	Robust IP portfolio + licensing revenue

8. IP Risks & Mitigations

Risk	Probability	Impact	Mitigation
Patent applications rejected	Medium (40%)	Medium	Prioritize first patent to issue; design-around strategies; trade secret backup
Competitor obtains blocking patent	Low (20%)	High	FTO analysis early; design-around documented; defensive publication
Trade secrets compromised	Low (10%)	High	Access controls, employee training, cyber insurance, NDAs enforced
IP litigation with competitor	Low (5%)	High	IP insurance ($1-2M coverage); early FTO assessment; IP counsel retainer
Data breach compromising proprietary data	Medium (20%)	High	Security infrastructure (SOC 2, HIPAA), cyber insurance, incident response

9. IP Strategy Alignment with Business Goals

9.1 Year 1-3 Focus: Establish Defensibility

- Secure patent filings (establish prior art dates)
- Build trade secret protection infrastructure
- Obtain HITRUST certification (regulatory moat)
- Publish clinical findings (establish credibility, support patent applications)

9.2 Year 3-5 Focus: Realize Value

- First patents issue (market differentiation)
- Begin licensing negotiations with EHR vendors
- Pharma partnerships for data licensing
- FDA Digital Therapeutic pre-submission (if pursuing)

9.3 Year 5-10 Focus: Maximize Licensing Revenue

- Active patent licensing (EHR, health systems, pharma)
- Consider strategic acquisition (IP portfolio valuable in M&A)
- International expansion (patent enforcement across geographies)
- Platform ecosystem partnerships (leverage IP for market leadership)

Conclusion

IHEP's intellectual property strategy balances three key objectives:

1. **Patent Protection:** Establish defensible IP covering core digital twin, federated learning, and morphogenetic self-healing innovations (estimated 70% probability of 1-2 patents issuing within 30 months)
2. **Trade Secret Protection:** Maintain competitive advantages through proprietary algorithms, datasets, and implementation methodologies (estimated $5-10M business value)
3. **Regulatory Moats:** Pursue FDA Digital Therapeutic pathway and HITRUST certification to create durable competitive barriers

Combined Value: IP portfolio estimated at $10-20M at Series A (based on healthtech SaaS IP multiples of $0.50-$1.00 per ARR dollar)

The IP strategy is complementary to IHEP's broader competitive advantages (network effects, data advantages, team execution) and significantly de-risks long-term market position through diversified protection mechanisms.

Document Control
Classification: Legal/IP Due Diligence - Confidential
Version: 1.1
Last Updated: November 26, 2025
Legal Counsel: [IP Law Firm Name] (external counsel retained)